2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On November 5, 2026, Our Bond, Inc. and Ascent Partners Fund LLC amended their Securities Purchase Agreement dated November 3, 2026. The amendment modifies certain covenant restrictions on the company's subsequent equity sales. The 8-K does not state the specific changes or any dollar amounts, so the effect on shareholders is not quantified in the filing.
Amendment dated November 5, 2026, to the Securities Purchase Agreement dated November 3, 2026, with Ascent Partners Fund LLC
Modifies covenant restrictions on the company's subsequent equity sales
Amendment filed as Exhibit 10.1; the 8-K does not give specific terms or figures
TechPrecision and its subsidiaries Ranor and Stadco entered a $10.0 million credit agreement with Rosenthal & Rosenthal on November 3, 2026, and used the proceeds to repay the prior Beacon Bank & Trust loan agreement. The facility includes a revolving line of up to $5.0 million and two term loans, and it requires a minimum quarterly tangible net worth of $5.5 million. The company also said it may be unable to file its Form 10-Q for the period ended September 30, 2026 on time.
Facility includes a $5.0 million revolving line, a $1.5 million three-year term loan and a $3.5 million five-year term loan, secured by substantially all personal property and a first mortgage on Ranor's Westminster, Massachusetts facility
Prior Beacon Bank & Trust loan agreement was terminated and repaid in full on November 3, 2026; closing costs were approximately $0.6 million.
Company issued 25,000 shares of common stock to the broker that introduced the lender.
Management expects the financing to alleviate the substantial doubt about going concern; tangible net worth was $7.6 million as of June 30, 2026 against the $5.5 million covenant.
On November 6, 2026, U.S. GoldMining agreed to sell 408,163 common shares at $4.90 each to an institutional investor in a registered direct offering. Gross proceeds are expected to be about $2.0 million before offering expenses, with closing expected on or about November 9, 2026. The company plans to use the net proceeds for working capital and general corporate purposes.
Shares offered: 408,163 common shares at $4.90 per share
Expected gross proceeds: approximately $1,999,998.70 before offering expenses
Offering made under an effective Form S-3 shelf registration (File No. 333-279435) and a prospectus supplement dated November 6, 2026
Expected closing on or about November 9, 2026, subject to customary conditions
UWM Holdings Corporation announced the final subscription price for its rights offering of up to 200,000,000 Class A common shares: $2.00 per share. The price is the greater of $2.00 and 85% of the 10-day volume-weighted average NYSE sales price ending November 9, 2026, so the $2.00 floor applied. Subscription rights expire at 5:00 p.m. Eastern Time on November 12, 2026, unless extended.
Final subscription price is $2.00 per share, the greater of $2.00 and 85% of the 10-day volume-weighted average price ending November 9, 2026.
The rights offering covers up to 200,000,000 shares of Class A common stock.
Subscription rights expire at 5:00 p.m. Eastern Time on November 12, 2026, unless extended.
Exercised rights can be withdrawn until 5:00 p.m. Eastern Time on November 10, 2026, unless the offering is extended; the company may amend, withdraw or terminate the offering with consent of the Backstop Purchasers.
American Tower priced three registered senior unsecured note offerings totaling $1.5 billion on November 9, 2026. The notes are fungible with existing notes issued on September 14, 2026, and expected net proceeds are $1,474.9 million, which the company intends to use to repay borrowings under its $6.0 billion revolving credit facility and for general corporate purposes.
2031 notes: $450.0 million at a 5.300% interest rate, priced at 99.387% of face value
2033 notes: $500.0 million at a 5.560% interest rate, priced at 99.369% of face value
2036 notes: $550.0 million at a 5.750% interest rate, priced at 98.986% of face value
Expected net proceeds of $1,474.9 million, to repay revolver borrowings and for general corporate purposes
Vistra Corp. filed a prospectus supplement to its automatic shelf registration statement on Form S-3 on November 9, 2026, for the issuance and sale of securities. This 8-K was filed only to attach the Latham & Watkins LLP opinion on the legality of those securities. The filing does not state the size, type, or pricing of the securities offered.
Prospectus supplement filed November 9, 2026 under shelf registration No. 333-298811
Purpose of this 8-K is solely to file the Latham & Watkins LLP legality opinion as Exhibit 5.1
Consent of Latham & Watkins LLP included as Exhibit 23.1; the filing does not state offering amount or terms
On November 9, 2026, Humana Inc. announced cash tender offers for eight series of its outstanding senior notes, with an aggregate purchase cap of $1.5 billion excluding accrued coupon payments. The offers expire at 5:00 p.m. New York City time on November 16, 2026, with settlement expected November 18, 2026. The filing is a debt management action and does not state its effect on earnings or guidance.
Aggregate purchase cap of $1.5 billion, excluding accrued coupon payments, subject to proration and acceptance priority levels
Series cap of $800 million on the 5.375% Senior Notes due 2031
Offers expire 5:00 p.m. New York City time on November 16, 2026; pricing is set on the same day at 3:00 p.m.
Expected settlement date is November 18, 2026; dealer managers include Barclays, BofA Securities, PNC and U.S. Bancorp
On November 9, 2026, Equinix Europe 2 Financing Corporation, an indirect wholly-owned subsidiary, issued €2.5 billion of senior notes in four series, fully and unconditionally guaranteed by Equinix, Inc. The notes carry fixed coupons from 4.150% to 5.450% and mature between 2028 and 2038, and Equinix intends to allocate the proceeds to eligible green projects. For shareholders, this adds debt to the company's balance sheet, though the filing does not compare it with existing debt levels.
€650 million 4.150% notes due November 9, 2028, and €700 million 4.800% notes due February 15, 2033
€500 million 5.100% notes due November 9, 2035, and €650 million 5.450% notes due November 9, 2038
Net proceeds are intended for eligible green projects; pending allocation, they may be held in cash or used to repay existing borrowings
Equinix hedged part of the interest rate risk on the 2035 and 2038 notes, with effective all-in rates of 4.91% and 5.42%
Orchestra BioMed sold 15,000,000 shares of common stock at $5.00 per share under an underwritten public offering priced November 5, 2026, and the offering closed November 9, 2026. The underwriters' 2,250,000-share option was exercised in full on November 6, 2026, and the filing puts gross proceeds at approximately $86.3 million before underwriting discounts and expenses, with the company citing the AVIM Therapy program, the BACKBEAT pivotal trial, and the Virtue SAB program as intended uses.
Offering: 15,000,000 shares at $5.00 per share, priced November 5, 2026, with Piper Sandler and TD Securities as representatives of the underwriters
Underwriters' 30-day option for 2,250,000 additional shares was exercised in full on November 6, 2026
Gross proceeds of approximately $86.3 million before underwriting discounts, commissions and other offering expenses; offering closed November 9, 2026
Stated uses: AVIM Therapy program, BACKBEAT global pivotal trial, Virtue SAB program and its coronary in-stent restenosis trial, other product candidates, and working capital
Texas Instruments completed the sale of $2 billion of senior notes on November 9, 2026, split into four $500 million tranches maturing in 2028, 2031, 2033 and 2036. The filing is a debt financing that adds to the company's borrowings, and it sets coupons of 5.000% to 5.750%, which shareholders may weigh against the cost of that debt.
Four $500 million tranches: 5.000% notes due 2028, 5.350% due 2031, 5.500% due 2033 and 5.750% due 2036
Sold under an underwriting agreement dated October 26, 2026 with J.P. Morgan Securities LLC, Citigroup Global Markets Inc., BofA Securities, Inc. and U.S. Bancorp Investments, Inc. as representatives
Issued under a 2011 indenture with U.S. Bank Trust Company, National Association, as trustee, and offered under a Form S-3 filed February 14, 2025
NiSource Inc. closed the sale of $600 million of 5.400% senior notes due 2032 on November 9, 2026, under an existing shelf registration. The company said it plans to use the net proceeds for general corporate purposes, including capital expenditures, working capital and repaying existing debt. This is a routine debt financing that adds to the company's borrowings but the filing does not give any effect on earnings or guidance.
Principal amount: $600 million of 5.400% Notes due 2032
Terms Agreement dated November 2, 2026; sale closed November 9, 2026
Lead underwriters: BMO Capital Markets, KeyBanc Capital Markets, Mizuho Securities USA and PNC Capital Markets
Proceeds for general corporate purposes, including capital expenditures, working capital and debt repayment
On November 9, 2026, CRH America Finance, a wholly owned subsidiary of CRH plc, completed the sale of four series of U.S. dollar guaranteed notes, fully guaranteed by CRH plc, with principal amounts totaling $4.2 billion. The company said net proceeds are expected to fund tender offers for outstanding Arcosa, Inc. notes, repay existing debt and support general corporate purposes, which adds to CRH's debt obligations while refinancing and reshaping its borrowings.
Four series issued: $1.35 billion 5.375% notes due 2032, $1.0 billion 5.625% notes due 2034, $1.35 billion 5.750% notes due 2037, and $500 million 6.250% notes due 2057
Notes were sold under an underwriting agreement dated November 4, 2026, with Barclays Capital, J.P. Morgan Securities and Morgan Stanley as representatives
Net proceeds are expected to finance tender offers for Arcosa, Inc. notes, repay existing debt and fund general corporate purposes
Innovative Industrial Properties amended its equity distribution agreements to add its 9.25% Series B Cumulative Redeemable Preferred Stock to its at-the-market offering program, alongside common stock and 9.00% Series A Preferred Stock. About $336.9 million of the program's $500 million capacity remained available as of the filing date, which gives the company a path to issue more shares that could dilute existing holders.
Program covers common stock, Series A Preferred Stock and Series B Preferred Stock, with aggregate offering price of up to $500 million
Approximately $336.9 million remained available for sale under the ATM Prospectus Supplement dated November 9, 2026
Amendments were entered into November 9, 2026 with BTIG, Piper Sandler, Roth Capital, Stifel, A.G.P./Alliance Global Partners and Huntington Securities
SS&C Technologies completed a private offering of $1.2 billion of 2.75% convertible senior notes due December 1, 2031, including a $150 million option exercised in full by the initial purchasers. The company plans to use the proceeds for capped call transactions, share repurchases of about $100 million, and redeeming its $2.0 billion of 5.500% Senior Notes due 2027, which adds debt and creates potential dilution if the notes convert.
Notes issued November 6, 2026 under an indenture with Wilmington Trust, National Association, as trustee, bearing interest at 2.75% payable June 1 and December 1.
Initial conversion price of about $99.46 per share, a premium of about 25.0% over the $79.57 closing price on November 4, 2026.
Proceeds planned for about $99 million capped call cost, about $100 million of share repurchases (about 1.3 million shares), and redemption of the $2,000.0 million 2027 Senior Notes.
Company may not redeem the notes before December 5, 2029, except in a cleanup redemption.
Jasper Therapeutics announced the results of its offer to purchase all outstanding warrants issued in its September 18, 2025 underwritten public offering, at $0.324 in cash per warrant, which expired on November 7, 2026. A total of 8,510,658 warrants were properly tendered, about 68.94% of the outstanding warrants, and the company expects to pay $2,757,453.19 in cash for them.
8,510,658 warrants were properly tendered and not withdrawn, about 68.94% of outstanding warrants.
Offer price was $0.324 in cash per warrant, without interest; the offer expired at 12:00 a.m. Eastern Time on November 7, 2026.
The company expects to pay an aggregate of $2,757,453.19 in cash, to be made promptly.
The offer was described in a Schedule TO originally filed with the SEC on October 7, 2026.
In the week of November 2 to November 8, 2026, Strategy reported $283.8 million in net proceeds from sales of its MSTR Class A common stock under its at-the-market program, and used $81.9 million of those proceeds to buy 1,036 bitcoin. It also spent $188.3 million repurchasing STRC preferred stock and held $146.2 million in USD Cash as of November 8.
MSTR common stock sales: 2,051,348 shares, $283.8 million net proceeds, with $18.3 billion still available for issuance
Bitcoin: 1,036 bitcoin bought for $81.9 million; aggregate holdings reached 850,364 bitcoin at an average purchase price of $75,456
STRC preferred repurchases: 1,887,464 shares for $188.3 million; $560.3 million remains under the preferred repurchase program
USD Reserve stood at $4.77 billion as of November 8, 2026, after $21.1 million was used for preferred dividends
Atea Pharmaceuticals entered a Loan and Security Agreement with Hercules Capital on November 6, 2026, providing for senior secured term loans of up to $200.0 million, with $65.0 million drawn at closing. The loans mature on November 1, 2031, and are secured by substantially all of the company's assets, including its intellectual property, which gives shareholders a larger fixed debt obligation tied to the company's development of BEM/RZR.
Tranche 1 loan of $65.0 million was drawn on the November 6, 2026 closing date; further tranches total up to $135.0 million
Interest floats at the greater of the WSJ prime rate plus 2.35% or 9.35%, paid monthly, with interest-only payments for 48 months
Tranche 2 availability depends on completing the Phase 3 trial of BEM/RZR before a specified date in the second half of 2027
Financial covenants include a minimum cash test beginning October 1, 2027, and a performance covenant tied to FDA approval of BEM/RZR
Precision BioSciences said it expects its November 5, 2026 share offering, along with existing cash, its at-the-market facility and continued cost discipline, to fund operations into the fourth quarter of 2029. The company projects it is sufficiently capitalized to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key next-stage inflection points. The filing does not state the net proceeds amount.
Offering of 10,235,077 common shares at $7.75 per share, under an underwriting agreement dated November 5, 2026
Pre-funded warrants for up to 5,893,964 shares offered in lieu of common stock to certain investors, at $7.749995 per warrant
Expected cash runway into the fourth quarter of 2029, covering PBGENE-HBV and PBGENE-DMD programs
SBA Communications entered a $2.0 billion senior unsecured Term Loan Credit Agreement on November 6, 2026. The company intends to use the $1.165 billion of initial term loans, funded at closing, to repay its Secured Tower Revenue Securities, Series 2021-1C, while $835.0 million of delayed draw commitments remain available until May 6, 2027.
Total facility of $2.0 billion: $1.165 billion funded on November 6, 2026 and $835.0 million of delayed draw term loan commitments
Initial term loans will repay the entire $1.165 billion of Secured Tower Revenue Securities, Series 2021-1C
Term loans mature November 6, 2029, do not amortize and can be prepaid without premium or penalty
Covenants include a Consolidated Total Net Leverage Ratio not to exceed 7.50 to 1.00 and a Consolidated Senior Secured Leverage Ratio not to exceed 3.50 to 1.00
FTAI Aviation's subsidiary issued $1.0 billion of 7.125% Senior Notes due November 15, 2034, on November 6, 2026. Net proceeds will repay its revolving credit facility, which was used to fund the parent's accelerated share repurchase program, and redeem $500.0 million of 5.50% notes due 2028.
Proceeds: repay in full the Revolving Credit Facility without a reduction in commitments, redeem $500.0 million of 5.50% Senior Notes due 2028, and pay fees
Notes are senior unsecured, fully guaranteed by FTAI Aviation Ltd., and offered only to qualified institutional buyers and non-U.S. persons
Valion Bio, Inc. issued 700 Series B Preferred Shares and warrants for 21,539 common shares to investor 3i, LP for $700,000 on November 6, 2026, under a side letter to an earlier agreement. The company also agreed to register the resulting common shares for resale and extended the deadline for further closings to December 9, 2027, which may add future dilution for shareholders.
Closing purchase price: $700,000 for 700 Series B Preferred Shares and warrants
Warrants cover 21,539 shares of common stock at an initial exercise price of $0.5182 per share
Registration statement to be filed within 30 days after closing and declared effective within 60 days
Outside date for closings under the Series B Preferred Purchase Agreement extended to December 9, 2027
Mangoceuticals' sole Series B preferred holder approved terms for a new 8% Series D convertible cumulative preferred stock and an amendment to the Series B designation, which would allow the company to sell up to 1,000,000 shares at $10.00 each under Regulation A. The company said the instruments are not yet filed or effective and it may not proceed with the offering; the company also set its combined 2025 and 2026 annual meeting for December 30, 2026.
On November 2, 2026, the holder of all 50 outstanding Series B preferred shares approved the Series D terms and Series B amendment by written consent.
Proposed Series D offering: up to 1,000,000 shares at $10.00 per share under Regulation A; no sales will occur before the SEC qualifies the offering statement on Form 1-A.
Annual meeting set for December 30, 2026 in Dallas, Texas; record date is November 12, 2026.
Shareholder proposals and director nominations for the meeting are due by November 16, 2026.
BioVie Inc. agreed on November 3, 2026 to sell shares and pre-funded warrants in a registered direct offering and common warrants in a concurrent private placement, with aggregate gross proceeds of approximately $4.74 million before fees and expenses. The offering closed on November 5, 2026, and the company intends to use the net proceeds for working capital and general corporate purposes. The deal adds shares and dilutive warrants, and the company has agreed to restrictions on new share issuances.
Registered direct offering: 960,000 shares at $1.60 per share plus 2,002,500 pre-funded warrants at $1.5999 each
Concurrent private placement: 2,962,500 common warrants exercisable at $1.70 per share, starting six months after issuance
Placement agent A.G.P./Alliance Global Partners receives a cash fee of 7.0% of gross proceeds
Company and directors and officers agreed to issuance and sale restrictions for 60 days after the November 5, 2026 closing
TuHURA Biosciences borrowed an additional $1.5 million on November 2, 2026, under the revolving credit facility from its April 21, 2026 Loan Agreement with Parkview Holdings One LLC. The facility has a maximum availability of $50 million and matures on April 21, 2031, and the company says it will use the funds for general corporate purposes.
Draw of $1,500,000 received and borrowed on November 2, 2026
Revolving facility with Parkview Holdings One LLC has maximum availability of $50 million
Facility matures April 21, 2031; the Loan Agreement was originally entered into April 21, 2026
Filing notes potential conflicts of interest because the lender is an affiliate of the company's largest stockholder
Santander Holdings USA, Inc. (SHUSA) said it will redeem all 6,000 outstanding shares of its Series H Preferred Stock and the corresponding 6,000,000 depositary shares on December 15, 2026. Depositary shares will be redeemed at $25.00 each, and the redemption price excludes the regular quarterly dividend, which is payable separately on the same date to holders of record on November 30, 2026.
Redemption date: December 15, 2026, covering 6,000 preferred shares and 6,000,000 depositary shares.
Redemption price: $25.00 per depositary share, not including the declared quarterly dividend.
Quarterly dividend: $0.328125 per depositary share, payable December 15, 2026 to holders of record as of November 30, 2026.
Redemption agent: Broadridge Corporate Issuer Solutions, LLC; shares are held through DTC.
Delta Air Lines completed a public offering of $500 million in 5.500% notes maturing November 6, 2029, on November 6, 2026. The company said it will use part of the proceeds to repay about $391 million of Payroll Support Program loan borrowings, about $70 million of aircraft-secured equipment notes, and, with cash on hand, about $39 million of pass through certificates, with any remainder for general corporate purposes. The filing adds new unsecured debt to the balance sheet while reducing several existing obligations.
Notes: $500 million aggregate principal, 5.500% coupon, maturing November 6, 2029
Interest paid semi-annually on May 6 and November 6, starting May 6, 2027
Proceeds to repay about $391 million Payroll Support Program loan, about $70 million equipment notes, and about $39 million pass through certificates
American Healthcare REIT entered into a new at-the-market equity sales agreement allowing it to sell up to $1.75 billion of common stock through a group of sales agents and forward purchasers. The company terminated its prior program, which had about $170 million left unsold, and says it will use any net proceeds for general corporate purposes, which may include future investments.
Agreement allows sales of common stock with an aggregate gross sales price of up to $1,750,000,000, replacing the prior program dated February 27, 2026.
About $170,134,000 remained unsold under the prior sales agreement when it was terminated.
Agents may receive a commission of up to 2.0% of gross sales price; shares are sold under a shelf registration statement on Form S-3 dated August 12, 2024.
Proceeds would go to the Operating Partnership for general corporate purposes, which may include potential future investments.
Silgan signed a consent to its credit agreement with Wells Fargo as administrative agent, letting lenders designate a new subsidiary, Silgan Metal Packaging LLC, as an unrestricted subsidiary. The change supports the planned contribution of several container and closure businesses to that entity under the October 17, 2026 Transaction Agreement. The filing gives no financial results or deal value, so the near-term effect on shareholders is not quantified here.
Consent to Amended and Restated Credit Agreement dated November 6, 2026, with Wells Fargo Bank, National Association, as Administrative Agent
Silgan Metal Packaging LLC (MetalCo) to be designated an Unrestricted Subsidiary, releasing it as a guarantor under the credit agreement
Business Contribution tied to the Transaction Agreement dated October 17, 2026 with A-VL Holdco, LP
If the MetalCo Transactions do not close, MetalCo and its subsidiaries will cease to be Unrestricted Subsidiaries
Energy Transfer LP priced $2.7 billion of senior notes in three equal $900 million tranches, due 2032, 2037 and 2057, with coupons of 5.450%, 5.900% and 6.550%. The offering is expected to settle on November 20, 2026, and the net proceeds of about $2.68 billion (before offering expenses) are intended to refinance existing debt, including commercial paper and revolving credit facility borrowings, and for general partnership purposes.
Three $900 million tranches: 5.450% notes due 2032, 5.900% notes due 2037 and 6.550% notes due 2057.
Prices to the public were 99.972%, 99.719% and 99.862% of face value, respectively.
Expected settlement date is November 20, 2026, subject to customary closing conditions.
Net proceeds of about $2.68 billion will refinance existing indebtedness and fund general partnership purposes; several underwriters' affiliates are lenders under the revolving credit facility and may receive a share of the repayment.
Enova International said subsidiary OnDeck Asset Securitization IV, LLC intends to offer $500,251,000 of Series 2026-2 fixed rate asset-backed notes in a private securitization backed by small business loans originated or purchased by its subsidiary ODK Capital, LLC. Closing is anticipated on or about November 13, 2026, subject to market and customary conditions, so the offering may not be completed as contemplated or at all. The notes will not be obligations of or guaranteed by Enova or OnDeck, and OnDeck expects to use substantially all proceeds for loan purchases from affiliates and general corporate purposes.
Four classes total $500,251,000: Class A $190,095,000 at 5.81%, Class B $118,744,000 at 6.15%, Class C $100,050,000 at 6.73%, Class D $91,362,000 at 8.57%.
Anticipated Kroll Bond Rating Agency ratings range from AA (sf) for Class A to BB- (sf) for Class D.
Notes are offered only to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S, and are not registered under the Securities Act.
Legal final payment date is December 19, 2033; the company announced the offering on November 3, 2026.
ACRES Commercial Realty Corp. entered into a Seventh Amendment to its Master Repurchase and Securities Contract Agreement with Morgan Stanley Mortgage Capital Holdings, which extends the agreement to November 2027 and modifies certain financial covenants in the related guaranty. The filing describes a routine financing amendment and does not disclose a borrowing amount, pricing, or fee figures beyond a reference to an unspecified Extension Fee.
Amendment dated November 2, 2026 extends the Morgan Stanley agreement to November 2027.
Company, as guarantor, agreed to amend certain financial covenants in its guaranty to Morgan Stanley.
Subsidiary ACRES Real Estate SPE 10, LLC is the seller; payment of an Extension Fee was due on or before November 3, 2026, amount not stated in the filing.
Zenas BioPharma filed a new prospectus supplement for an at-the-market offering of up to $200 million in common stock through Jefferies LLC, and ended the earlier program, under which it had sold about $153.2 million of shares with about $46.8 million unsold. The filing is a routine share-sale mechanism, and any sales would dilute existing shareholders, though the filing does not state whether or when any shares will be sold.
New prospectus supplement filed November 6, 2026, for up to $200,000,000 of common stock under the October 8, 2025 Sales Agreement with Jefferies LLC
Prior program terminated: about $153.2 million sold and about $46.8 million unsold at filing date
Shares to be offered under the existing Form S-3ASR registration statement, which became automatically effective upon filing
Ropes & Gray LLP legal opinion filed as Exhibit 5.1
NB Bancorp, Inc., the holding company of Needham Bank, issued $100 million of 7.50% fixed-to-floating subordinated notes due 2036 to institutional investors on November 6, 2026, at 100% of principal. The company estimates net proceeds of approximately $98,265,004.75 and plans to use them for general corporate purposes, including at least $30 million to increase the bank's Tier 1 capital, and the notes are intended to count as Tier 2 capital.
$100 million principal, maturing November 15, 2036, issued at 100% of principal in a private placement
Fixed rate of 7.50% until November 15, 2031, then resets quarterly to three-month SOFR plus 305 basis points
Estimated net proceeds of approximately $98,265,004.75; at least $30 million to be contributed to Needham Bank
Notes rated BBB- by Kroll Bond Rating Agency; Piper Sandler & Co. was sole placement agent
GATX Corporation agreed under an underwriting agreement dated November 2, 2026 to sell $300 million of 5.950% Senior Notes due 2036, and issued the notes to the underwriters on November 6, 2026. The filing describes a debt issuance rather than a change in operations, so its main significance for shareholders is the added long-term borrowing.
Principal amount: $300 million of 5.950% Senior Notes due 2036
Underwriting agreement dated November 2, 2026, with BofA Securities, Citigroup Global Markets and Morgan Stanley & Co. as representatives
Notes issued and delivered to underwriters against payment on November 6, 2026
Sold under shelf registration statement on Form S-3 (Registration No. 333-286436)
aTyr Pharma filed a prospectus supplement allowing it to sell common stock worth up to $79,994,251 from time to time under an existing open market sale agreement with Jefferies LLC. The filing sets up potential share issuance that could dilute existing shareholders, though the filing does not state how much stock has been or will be sold.
Maximum aggregate offering price of up to $79,994,251 under the Sales Agreement with Jefferies LLC, dated April 22, 2022, as amended December 23, 2024
Offering is made under Form S-3 shelf registration (File No. 333-289360), filed August 7, 2025 and declared effective August 18, 2025
Cooley LLP legal opinion on the legality of the shares filed as Exhibit 5.1
Public Storage Operating Company, a subsidiary of Public Storage, completed a $500 million offering of 5.600% Senior Notes due November 15, 2036, guaranteed by Public Storage. The filing describes new long-term unsecured debt with covenants limiting secured and unsecured borrowing and requiring unencumbered assets of at least 125% of unsecured indebtedness.
Principal amount of $500 million; interest at 5.600% per year, accruing from November 6, 2026
Interest payable semi-annually on May 15 and November 15, starting May 15, 2027; maturity November 15, 2036
Notes are unsecured and rank equally with existing and future unsecured debt of the issuer; redeemable at a make-whole price, or at 100% of principal from August 15, 2036
Offering made under a Form S-3 shelf registration; prospectus supplement dated October 29, 2026
Janus Living, Inc. closed a registered underwritten public offering of 30,187,500 Class A-1 common shares on November 6, 2026, including the underwriters' full exercise of their option to buy 3,937,500 additional shares. The filing does not state the offering price or the proceeds, and the issuance adds shares that will dilute existing holders' ownership.
Offering closed November 6, 2026 with 30,187,500 Class A-1 common shares, $0.01 par value
Underwriters exercised their option in full for 3,937,500 additional shares
Underwriting Agreement dated November 4, 2026 with BofA Securities, J.P. Morgan, Wells Fargo and Goldman Sachs as representatives
Repligen closed private exchange and subscription transactions on November 6, 2026, issuing $1.0 billion of 0.25% Convertible Senior Notes due 2031. About $541.4 million of the new notes swapped out $456.8 million of its 1.00% notes due 2028, and $458.6 million was sold for cash. The filing shows the company took on new debt with a lower coupon and a conversion price about 20% above the October 29, 2026 closing price, which could mean future share dilution if holders convert.
Issued $1.0 billion of 0.25% Convertible Senior Notes due November 1, 2031, with interest paid semi-annually starting May 1, 2027
Exchanged $456.8 million of 1.00% 2028 notes for $541.4 million of new notes; $143.2 million of 2028 notes remain outstanding
Initial conversion price of about $226.37 per share, roughly 20% above the $188.64 closing price on October 29, 2026
Up to 5,301,100 shares of common stock may be issued on conversion, including make-whole additional shares
PowerCompute entered into a Fourth Amendment to a Secured Promissory Note with Brown Family Enterprises LLC, effective October 31, 2026, extending the maturity of a $1,250,000 loan from December 31, 2026 to December 31, 2027. The filing describes a debt maturity extension only and does not state any change to the loan amount or other terms, so it defers repayment pressure by one year.
Loan principal amount: $1,250,000 from Brown Family Enterprises LLC
Maturity date extended from December 31, 2026 to December 31, 2027
Amendment dated October 31, 2026, agreement entered November 2, 2026
On November 5, 2026, EVERTEC's subsidiary Evertec Group, LLC refinanced its $387.8 million Term A loan and replaced its revolving facility under a seventh amendment to its credit agreement with Truist Bank as agent. Both facilities now mature on November 5, 2031, and revolving commitments rose from $200.0 million to $300.0 million. The company said pricing fell 25 basis points, and it paid the transaction costs with cash on hand.
Term A facility of $387.8 million refinanced through a cashless roll and now matures November 5, 2031, subject to a springing maturity tied to Term B loans.
Revolving commitments increased from $200.0 million to $300.0 million, with an additional $100 million incremental commitment fungible with the existing revolver.
Interest margins range from 1.25% to 2.25% for SOFR term loans and 0.25% to 1.25% for alternate base rate loans, based on the Total Net Leverage Ratio.
Term B loans maturing October 30, 2030 had $875 million outstanding as of November 6, 2026, and the filing says their terms are not affected.
TKO Group Holdings priced a $1.0 billion offering of 6.500% Senior Secured Notes due 2031, issued by its indirect subsidiary TKO Worldwide Holdings, LLC. The company said net proceeds may fund general corporate purposes, including distributions to parent entities to fund share repurchases under its existing program. The offering adds $1.0 billion of secured debt, which shareholders may weigh against the planned buybacks.
Pricing announced November 5, 2026: $1.0 billion aggregate principal amount of 6.500% Senior Secured Notes due 2031
Issuer is indirect subsidiary TKO Worldwide Holdings, LLC; notes guaranteed by TKO Guarantor, LLC and certain subsidiaries
Proceeds may fund share repurchases under TKO's previously announced program, plus fees and expenses
Closing expected on or about November 13, 2026, subject to customary conditions
On November 2, 2026, Public Policy Holding Company, Inc. (PPHC) entered a $105 million senior secured credit facility with Bank of America, N.A. as administrative agent, and used it to repay and terminate its existing credit agreement. The facility consists of a $65 million term loan and a $40 million revolving credit facility, maturing November 2, 2031, and the company says proceeds will also fund the Reevemark acquisition and working capital.
Facility of $105 million: a $65 million term loan and a $40 million revolving credit facility, maturing November 2, 2031
$65 million was borrowed under the term loan at closing
Interest is SOFR plus 185 to 230 basis points, set by net leverage; the company plans syndication to $150 million, expected to close January 2027 on a best-efforts basis
Existing credit agreement dated February 28, 2023 was repaid and terminated
CBRE Services, a wholly-owned subsidiary of CBRE Group, completed a $1 billion offering of senior notes in two $500 million tranches due 2032 and 2037. The Company intends to use the proceeds for general corporate purposes, including repaying commercial paper borrowings and funding the pending acquisition of Onnec Group Limited, which adds debt that shareholders will need to service.
$500 million of 5.650% Senior Notes due January 15, 2032, with semi-annual interest beginning January 15, 2027
$500 million of 5.900% Senior Notes due January 15, 2037, with semi-annual interest beginning January 15, 2027
Notes are fully and unconditionally guaranteed on a senior unsecured basis by CBRE Group, Inc.
Proceeds intended for commercial paper repayment and the pending acquisition of Onnec Group Limited
Meta Platforms completed a $15.0 billion offering of five U.S. dollar senior note series maturing from 2031 to 2056, with fixed rates from 5.850% to 7.500%. Underwriters also exercised in full their option to buy 6,000,000 additional Class A common shares from an offering priced in late October 2026, with forward sale agreements covering those shares. The filing does not state how the proceeds will be used, so the added debt and share sales are the main points for shareholders to weigh.
Five senior note series: $3.25 billion due 2031, $3.25 billion due 2033, $4.0 billion due 2036, $1.75 billion due 2046 and $2.75 billion due 2056
Notes were issued under an indenture dated August 9, 2022 with U.S. Bank Trust Company, National Association, as trustee, and a sixth supplemental indenture dated November 5, 2026
Underwriters exercised their option in full on November 4, 2026 for 6,000,000 additional Class A common shares, with additional forward sale agreements on similar terms
Underwriting agreement dated November 3, 2026 with Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC as representatives
CVR Energy agreed to sell 10,515,248 common shares at $47.55 each, with net proceeds of about $490.0 million before offering expenses, closing November 5, 2026. The company plans to use the proceeds with cash on hand and other financing to fund its acquisition of the St. Paul Park and Mandan refineries from Marathon Petroleum subsidiaries, redeem its 5.750% Senior Notes due 2028, and pay related fees.
Offering: 10,515,248 shares at $47.55 per share, with a 30-day option for up to 1,577,287 additional shares
Net proceeds of approximately $490.0 million; offering closed November 5, 2026
Proceeds to fund the St. Paul Park and Mandan refinery acquisition and redeem 2028 Notes; if the acquisition does not close, proceeds go to general corporate purposes
Selling stockholder IEP Energy Holding LLC is not included in the priced offering; the company receives no proceeds from its shares
Otis Worldwide issued $500 million of 5.825% notes maturing November 5, 2036, with estimated net proceeds of about $495.3 million. The company plans to use the proceeds with cash on hand to repay its 2.293% notes due April 5, 2027, which had $500 million outstanding as of September 30, 2026. This is a routine debt refinancing that replaces near-term maturing debt with longer-dated debt at a higher stated interest rate.
Notes: $500 million principal, 5.825% annual interest, maturing November 5, 2036; interest payable May 5 and November 5 starting May 5, 2027
Estimated net proceeds of about $495.3 million, to repay 2.293% notes due April 5, 2027 ($500 million outstanding at September 30, 2026)
Notes are unsecured and rank equally with existing unsecured debt; make-whole redemption before August 5, 2036; 101% change of control put
Xometry issued a notice to redeem all approximately $85.0 million of its 1.00% Convertible Senior Notes due 2027, with redemption set for November 20, 2026, at 100% of principal plus accrued interest. Holders may still convert the notes into Class A common stock until 5:00 p.m. New York City time on November 19, 2026, and the filing says conversions after the notice will settle in physical shares. The filing is a debt-management step and gives no results or guidance figures.
Notes to be redeemed: all approximately $85.0 million aggregate principal of 1.00% Convertible Senior Notes due 2027
Redemption date: November 20, 2026, at 100% of principal plus accrued and unpaid interest from August 1, 2026
Conversion deadline: 5:00 p.m. New York City time on November 19, 2026; each $1,000 converts into 17.8213 shares, plus 0.0018 additional shares for conversions before the deadline
Live Oak Bancshares agreed on November 4, 2026 to sell 4,000,000 depositary shares, each representing a 1/40th interest in its 8.750% Series B non-cumulative perpetual preferred stock, at a $25 liquidation value per depositary share. The company expects the offering to close on or about November 12, 2026, and says the net proceeds will fund general corporate purposes, including balance sheet growth at Live Oak Banking Company and its capital position.
Underwriters are Morgan Stanley & Co. LLC, Keefe, Bruyette & Woods, RBC Capital Markets and UBS; the underwriters have a 30-day option for up to 600,000 additional depositary shares.
Dividends are 8.750% per annum, payable quarterly when declared by the board, beginning December 15, 2026.
The company may redeem the Series B preferred stock on or after December 15, 2031, or after a regulatory capital treatment event, at $1,000 per share ($25 per depositary share).
Live Oak intends to list the depositary shares on the NYSE under the symbol LOB/PB.
Xcel Energy issued $2.5 billion of 2.625% convertible senior notes due December 15, 2027, including $300 million from the initial purchasers' option. The notes are convertible into Xcel common stock at an initial conversion price of about $87.26 per share, and conversions can be settled in cash, shares, or a mix. Because the notes are convertible, they could add up to 31,513,750 shares of common stock to the share count if holders convert at the maximum rate.
Issued $2,500,000,000 of 2.625% Convertible Senior Notes due December 15, 2027, dated November 5, 2026
Initial conversion rate of 11.4596 shares per $1,000 principal, or about $87.26 per share
Up to 31,513,750 shares may be issued on conversion at the initial maximum conversion rate of 12.6055 shares per $1,000
Notes cannot be redeemed by Xcel Energy before maturity and carry no sinking fund
Enova International priced a private offering of $600 million in senior notes due 2031 at par, bearing 8.750% annual interest, with closing expected November 20, 2026. The company plans to use the proceeds to redeem all of its 11.25% senior notes due 2028 on December 15, 2026, pay offering fees, and repay part of its revolving credit facility borrowings, which refinances higher-rate debt for shareholders to watch.
Offering size: $600 million aggregate principal amount of senior notes due 2031, priced at 100.000% of principal
Interest rate: 8.750% per annum; notes are senior unsecured and guaranteed by domestic subsidiaries
Expected closing: November 20, 2026, subject to customary conditions
Use of proceeds: redeem all 11.25% senior notes due 2028 on December 15, 2026, and repay part of revolver borrowings
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.